GlassScriptPhysician profile
Alan S Lichtbroun
NPI 1003855628
$1,382.27
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $293 · 2021: $28.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $229.56 | 2019-2020 | |
| Abbvie INC. | $200.65 | 2019-2020 | |
| Genzyme Corporation | $157.81 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $132.76 | 2019-2020 | |
| Genentech USA, INC. | $119.08 | 2019 | |
| Pfizer INC. | $85.40 | 2019-2020 | |
| Horizon Therapeutics Plc | $83.05 | 2019-2021 | |
| Glaxosmithkline, LLC. | $79.20 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $56.90 | 2019 | |
| Lilly USA, LLC | $55.08 | 2019-2020 | |
| Janssen Biotech, INC. | $41.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.19 | 2020 | |
| Mallinckrodt Hospital Products INC. | $26.22 | 2020 | |
| Radius Health, INC. | $24.65 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.97 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13.44 | 2019 | |
| Biodelivery Sciences International, INC. | $13.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Lichtbroun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.